A new Phase 2a clinical trial, funded by The Michael J. Fox Foundation (MJFF), is now recruiting Parkinson’s disease patients to test the safety and tolerability of nilotinib, an approved treatment for chronic myelogenous leukemia (CML) that is now being repurposed for Parkinson’s disease.
Nilotinib, marketed as Tasigna for CML, is a tyrosine kinase inhibitor that blocks the c-Abl protein in leukemia cells with an abnormal chromosome, called the Philadelphia chromosome, stopping them from growing. But studies suggest that c-Abl also is involved in cellular pathways associated with Parkinson’s disease, suggesting that nilotinib could hold promise for this neurodegenerative disease.
The trial aims to enroll a total of 75 people with moderate-to-advanced Parkinson’s and will be conducted in a maximum of 25 clinical sites across the United States. Patients willing to participate are encouraged to visit the Fox Trial Finder to view a list of recruiting sites and eligibility criteria.
Participants will be randomized to daily doses of nilotinib or placebo for a period of six months. They will be closely monitored during the trial period and for an additional eight weeks after all treatments ceased.
The results will allow researchers to evaluate both nilotinib’s safety and tolerability, and to determine the therapy’s maximum tolerated dose.
The effectiveness of nilotinib for halting Parkinson’s symptoms and/or disease progression will be determined via a comprehensive analysis that includes complete motor, cognitive, and biological (i.e., blood and spinal fluid) tests.
If researchers find conclusive proof of nilotinib’s safety, a second trial is set up to include s60 participants with early Parkinson’s disease to test nilotinib for a period of 12 months at the highest tolerated daily dose. The trial also will include a placebo control group.
Principal investigator Tanya Simuni, MD, professor of neurology and head of the division of movement disorders at Northwestern University Feinberg School of Medicine, is leading the trial. It is set up with the collaboration of the Parkinson Study Group, which is the largest non-profit scientific network of Parkinson’s disease centers in North America.
Nilotinib, developed by Novartis, is an example of drugs that are being repurposed (aka “repositioned”) for Parkinson’s disease. This strategy has several advantages, as approved drugs for another condition are already known to be safe in humans. As a result, repurposed drugs usually can skip Phase 1 clinical testing, but still need to go through Phase 2 and Phase 3 trials to determine its effectiveness in other disease settings.
“Repurposing is a promising path to new Parkinson’s treatments, but we must demonstrate the safety and efficacy of therapies specifically for PD,” Todd Sherer, PhD, CEO at MJFF, said in a press release. “As part of our no-stone-unturned approach, The Michael J. Fox Foundation pursues every avenue, including repurposing, to accelerate breakthroughs for patients who urgently need them.”